Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Foghorn Therapeutics (FHTX) Invested Capital: 2020-2025

Historic Invested Capital for Foghorn Therapeutics (FHTX) over the last 6 years, with Sep 2025 value amounting to -$89.7 million.

  • Foghorn Therapeutics' Invested Capital fell 216.96% to -$89.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$89.7 million, marking a year-over-year decrease of 216.96%. This contributed to the annual value of -$45.5 million for FY2024, which is 41.02% up from last year.
  • As of Q3 2025, Foghorn Therapeutics' Invested Capital stood at -$89.7 million, which was down 16.96% from -$76.7 million recorded in Q2 2025.
  • Over the past 5 years, Foghorn Therapeutics' Invested Capital peaked at $144.9 million during Q1 2021, and registered a low of -$97.5 million during Q1 2024.
  • In the last 3 years, Foghorn Therapeutics' Invested Capital had a median value of -$57.4 million in 2023 and averaged -$56.6 million.
  • As far as peak fluctuations go, Foghorn Therapeutics' Invested Capital soared by 243.18% in 2021, and later crashed by 69,019.64% in 2023.
  • Foghorn Therapeutics' Invested Capital (Quarterly) stood at $96.9 million in 2021, then slumped by 99.88% to $112,000 in 2022, then tumbled by 69,019.64% to -$77.2 million in 2023, then soared by 41.02% to -$45.5 million in 2024, then crashed by 216.96% to -$89.7 million in 2025.
  • Its last three reported values are -$89.7 million in Q3 2025, -$76.7 million for Q2 2025, and -$61.7 million during Q1 2025.